Fullerene compounds as antioxidant therapy

US2016331698A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2016331698-A1
Application numberUS-201515111331-A
CountryUS
Kind codeA1
Filing dateJan 13, 2015
Priority dateJan 13, 2014
Publication dateNov 17, 2016
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Disclosed herein are small-gap fullerene compositions and methods of using for therapeutic or cosmetic purposes. Specifically exemplified is the use of derivatized SGFs so as to be water-soluble. The derivatized SGFs include polyhydroxylated and polycarboxylated SGFs.

First claim

Opening claim text (preview).

What is claimed is: 1 . A method of treating or preventing an unwanted condition, disease or symptom of a patient associated with oxidative stress comprising administering a therapeutically effective amount or prophylactically effective amount of a small-gap fullerene (SGF) composition to a subject in need. 2 . The method of claim 1 , wherein said SGF composition comprises SGF compounds ranging from a size of C 60 to C 400 . 3 . The method of claim 1 , wherein the SGF composition comprises SGFs with at least fifty percent being water-soluble SGFs. 4 . The method of claim 3 , wherein the water-soluble SGFs comprise polyhydroxylate SGFs (PSGFs) or polycarboxylated SGFs. 5 . The method of claim 2 , wherein said SGF composition comprises a peak distribution of SGF compounds of a size between about C 100 to C 200 . 6 . The method of claim 5 , wherein said peak distribution comprises SGF compounds of a size of about C 120 . 7 . The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier. 8 . The method of claim 1 , wherein the oxidative stress is associated with Abeta. 9 . The method of claim 1 , wherein the unwanted condition is a neurodegenerative disease. 10 . The method of claim 9 , wherein the neurodegenerative disease is Alzheimer's disease, Parkinson's disease, or Dementia with Lewy Bodies. 11 . A method for improving the general condition and appearance of skin, the method comprising administering a cosmetically effective amount of a SGF composition to a patient for cosmetic purposes. 12 . The method of claim 11 , wherein said SGF composition is administered topically. 13 . The method of claim 11 , wherein said method diminishes the appearance of wrinkles. 14 . The method of claim 11 , wherein said SGF composition comprises SGF compounds ranging from a size of C 60 to C 400 . 15 . The method of claim 11 , wherein the SGF composition comprises SGFs with at least fifty percent being water-soluble SGFs. 16 . The method of claim 15 , wherein the water-soluble SGFs comprise polyhydroxylate SGFs (PSGFs) or polycarboxylated SGFs. 17 . The method of claim 11 , wherein said SGF composition comprises a peak distribution of SGF compounds of a size between about C 100 to C 200 . 18 . A composition formulated for topical administration, said composition comprising SGFs and cosmetically acceptable carrier. 19 . The composition of claim 18 , further comprising at least one conjunctive agent. 20 . The composition of claim 19 , wherein said conjunctive agent comprises sun blocking agents, acute or chronic moisturizing agents, anti-oxidants, sunscreens having UVA and/or UVB protection, emollients, anti-irritants, vitamins, trace metals, anti-microbial agents, botanical extracts, fragrances, dyes and color ingredients, structuring agents, and/or emulsifiers 21 . The composition of claim 18 , wherein SGFs comprises at least 50 percent PSGFs.

Assignees

Inventors

Classifications

  • Free radical scavengers or antioxidants · CPC title

  • for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

  • Anti-Parkinson drugs · CPC title

  • Drugs for disorders of the nervous system · CPC title

  • Emollients or protectives, e.g. against radiation · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2016331698A1 cover?
Disclosed herein are small-gap fullerene compositions and methods of using for therapeutic or cosmetic purposes. Specifically exemplified is the use of derivatized SGFs so as to be water-soluble. The derivatized SGFs include polyhydroxylated and polycarboxylated SGFs.
Who is the assignee on this patent?
Sugaya Kiminobu, Torres Alexander, Univ Central Florida Res Found Inc
What technology area does this patent fall under?
Primary CPC classification A61Q19/08. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Thu Nov 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).